MISSISSAUGA, ON, Oct. 23, 2024–(BUSINESS WIRE)–MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) in a press release dated August 6, 2024 In addition, we are announcing the following: The TSXV has issued a final agreement dated August 14, 2024 with respect to the modification of the $3,700,000 outstanding balance of the Series I Loan Notes issued in 2021 by extending the maturity date from December 31, 2023 to December 31, 2023. A letter of acceptance was issued. It was scheduled for 2025, but later withdrew its final approval. The Company is currently filing an amended final acceptance application to extend the maturity date of the Series I Loan Notes only with respect to $2,650,000 of the Series I Loan Notes for which an extension agreement has been entered into. If any of the holders of the Series I Loan Notes who have not yet signed an extension agreement decide to accept the extension, the Company may submit a request for acceptance to the TSXV and its issuance will be subject to the applicable terms and conditions. applies. TSXV Policy.
Some holders of Series I Loan Notes who agreed to the extension and held an aggregate amount of $150,000 were referred to Multilateral Instrument 61-101 – Protection of Minority Securities Holders in Special Transactions (“ MI 61-101 ”). In connection with the extension of the maturity date of the Series I Loan Notes, the Company is relying on the exemption from the formal appraisal and minority shareholder approval requirements set forth in Section 5.7(1)(a) of MI 61-101 .
About MedX Health Corp.:
Headquartered in Ontario, Canada, MedX is a leading medical device and software company focused on skin health with SIAscopy® on the DermSecure® telemedicine platform powered by SIAscopy® technology. SIAscopy® is also incorporated into the products SIAMETRICS®, SIMSYS®, and MoleMate®, manufactured by MedX in an ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include handheld devices that use patented technology that utilizes light and its transmission to painlessly and non-invasively target suspicious moles or lesions up to 2 mm below. You can observe it in – Time images that allow doctors and dermatologists to assess all types of moles and lesions within seconds. These products are approved for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil, and Turkey by Health Canada, the U.S. Food and Drug Administration, the Drug Administration, and Conformité Européenne. Visit https://medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This media release may contain forward-looking statements that reflect the Company’s current expectations regarding future events. Forward-looking statements involve risks and uncertainties.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241023760652/en/
story continues
contact address
Bill Mitoulas, Investor Relations
Medex Health Corporation
bill@medxhealth.com
+1-416-479-9547
or
Stephen Lockyer, President
+1-905-670-4428
